Aquestive Therapeutics (AQST) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order with agenda and rules of conduct available on the virtual site.

• Attendees included board members, senior leadership, independent auditors, and election inspectors.

• Stockholders could submit questions throughout the meeting and during a dedicated Q&A session.

Board and executive committee updates

• Board members and senior leadership, including CEO, CFO, and other key officers, were introduced.

• Representatives from KPMG and Broadridge Financial Solutions were present.

Strategic initiatives and plans

• Focus on FDA acceptance of NDA for Anaphylm, aiming for resubmission in Q3 2026.

• Commercial launch preparations for Anaphylm targeted for early 2027, with a 75-person sales force.

• Global regulatory progress in the U.K., Europe, and Canada, with no further clinical work required for submissions.

• Pipeline development includes AQST-108, with promising phase I safety results in androgenic alopecia.